{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T04:33:06Z","timestamp":1793075586379,"version":"4.5.0"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009945","name":"Merck KGaA","doi-asserted-by":"publisher","award":["CrossRef Funder ID: 10.13039\/100009945"],"award-info":[{"award-number":["CrossRef Funder ID: 10.13039\/100009945"]}],"id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofliquidbiopsy.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Liquid Biopsy"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.jlb.2026.100504","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T16:28:55Z","timestamp":1789662535000},"page":"100504","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Circulating tumor DNA tumor fraction as a biomarker in refractory metastatic colorectal cancer: findings from the CAVE-2 GOIM trial"],"prefix":"10.1016","volume":"14","author":[{"given":"Davide","family":"Ciardiello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Martini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Boscolo Bielo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria","family":"Pellizzari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Pietrantonio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Andena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Marchesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Pisconti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Nisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giampaolo","family":"Tortora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Salvatore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Sartore-Bianchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Siena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Papaccio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Messina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Ongaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Zaniboni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmine","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Antonuzzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Avallone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Normanno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Santabarbara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Giulia","family":"Zampino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra Pia","family":"D'Agata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossana","family":"Berardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessio","family":"Cogoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Lotesoriere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiziana Pia","family":"Latiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carminia Maria","family":"Della Corte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Fazio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Curigliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Bordonaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Troiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferdinando","family":"De Vita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Martinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fortunato","family":"Ciardiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Napolitano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.jlb.2026.100504_bib1","doi-asserted-by":"crossref","first-page":"308","DOI":"10.3390\/biomedicines8090308","article-title":"The liquid biopsy in the management of colorectal cancer: an overview","volume":"8","author":"Vacante","year":"2020","journal-title":"Biomedicines"},{"issue":"4","key":"10.1016\/j.jlb.2026.100504_bib2","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.5635","article-title":"Anti-EGFR rechallenge in patients with refractory ctDNA RAS\/BRAF wt metastatic colorectal cancer: a nonrandomized controlled trial","volume":"7","author":"Ciardiello","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jlb.2026.100504_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2026.105180","article-title":"Anti-EGFR rechallenge compared with standard of care for patients with ctDNA RAS\/BRAF wild-type chemorefractory metastatic colorectal cancer: a systematic review and meta-analysis","volume":"220","author":"Kuznetsova","year":"2026","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.jlb.2026.100504_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2026.03.005","article-title":"Metastatic colorectal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","author":"Cremolini","year":"2026","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.jlb.2026.100504_bib5","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1093\/annonc\/mdy509","article-title":"Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge","volume":"30","author":"Parseghian","year":"2019","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.jlb.2026.100504_bib6","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/s41591-023-02791-w","article-title":"Baseline ctDNA gene alterations as a biomarker of survival after panitumumab and chemotherapy in metastatic colorectal cancer","volume":"30","author":"Shitara","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.jlb.2026.100504_bib7","doi-asserted-by":"crossref","unstructured":"Martelli V, Barrull J, Cirac\u00ec P et al. 71P Early- versus late-onset RAS wild-type (RASWT) metastatic colorectal cancer (mCRC) patients receiving first-line (1L) anti-EGFR therapy: a pooled ctDNA analysis of three clinical trials Ann Oncol, 37, S26-S27.","DOI":"10.1016\/j.annonc.2026.05.072"},{"issue":"5","key":"10.1016\/j.jlb.2026.100504_bib8","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.3390\/ijms26052216","article-title":"Negative hyperselection in metastatic colorectal cancer for first-line Anti-EGFR therapy: a narrative review","volume":"26","author":"Ciappina","year":"2025","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jlb.2026.100504_bib9","doi-asserted-by":"crossref","unstructured":"Montagut C, Vidal J, Fernandex Rodrigues C, et al. Circulating tumour (ct) DNA-guided Anti-EGFR rechallenge strategy in metastatic colorectal cancer (mCRC): final results of the phase II randomized CITRIC trial. Presented at ESMO annual Congress, Berlin 17-21 October 2025, LBA33.","DOI":"10.1016\/j.annonc.2025.09.044"},{"issue":"1","key":"10.1016\/j.jlb.2026.100504_bib10","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.annonc.2022.09.163","article-title":"Prognostic value of plasma circulating tumor DNA fraction across four common cancer types: a real-world outcomes study","volume":"34","author":"Reichert","year":"2023","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.jlb.2026.100504_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105491","article-title":"Comprehensive genomic profiling by liquid biopsy in refractory metastatic colorectal cancer patients who are candidate for anti-EGFR rechallenge therapy: findings from the CAVE-2 GOIM trial","volume":"10","author":"Ciardiello","year":"2025","journal-title":"ESMO Open"},{"issue":"5","key":"10.1016\/j.jlb.2026.100504_bib12","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.annonc.2025.12.014","article-title":"Cetuximab rechallenge in molecularly selected metastatic colorectal cancer: the randomized CAVE-2 GOIM trial","volume":"37","author":"Ciardiello","year":"2026","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jlb.2026.100504_bib13","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.940523","article-title":"CAVE-2 (Cetuximab-AVElumab) mCRC: a phase II randomized clinical study of the combination of avelumab plus cetuximab as a rechallenge strategy in pre-treated RAS\/BRAF wild-type mCRC patients","volume":"12","author":"Napolitano","year":"2022","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.jlb.2026.100504_bib14","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/s41698-024-00685-9","article-title":"Tumor fraction-based prognostic tool for cancer patients referred to early phase clinical trials","volume":"8","author":"Bayle","year":"2024","journal-title":"npj Precis Oncol"},{"key":"10.1016\/j.jlb.2026.100504_bib15","article-title":"Role of circulating tumor DNA tumor fraction in advanced non-small cell lung cancer and its impact on patient treatment outcomes: a prospective real-world study","volume":"9","author":"Cheung","year":"2025","journal-title":"JCO Precis Oncol"},{"issue":"1","key":"10.1016\/j.jlb.2026.100504_bib16","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.annonc.2025.10.002","article-title":"Re-treatment with panitumumab followed by regorafenib versus the reverse sequence in chemorefractory metastatic colorectal cancer patients with RAS and BRAF wild-type circulating tumor DNA: the PARERE study by GONO","volume":"37","author":"Cirac\u00ec","year":"2026","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jlb.2026.100504_bib17","article-title":"Effects of metastatic sites on circulating tumor DNA in patients with metastatic colorectal cancer","volume":"6","author":"Bando","year":"2022","journal-title":"JCO Precis Oncol"},{"issue":"12","key":"10.1016\/j.jlb.2026.100504_bib18","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/j.annonc.2024.08.2334","article-title":"Comprehensive genomic profiling by liquid biopsy captures tumor heterogeneity and identifies cancer vulnerabilities in patients with RAS\/BRAFV600E wild-type metastatic colorectal cancer in the CAPRI 2-GOIM trial","volume":"35","author":"Ciardiello","year":"2024","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.jlb.2026.100504_bib19","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1002\/ijc.33303","article-title":"A higher ctDNA fraction decreases survival in regorafenib-treated metastatic colorectal cancer patients. Results from the regorafenib's liquid biopsy translational biomarker phase II pilot study","volume":"148","author":"Unseld","year":"2021","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jlb.2026.100504_bib20","article-title":"Chemotherapy response monitoring with DNA methylation-based ctDNA tumor fraction: evidence from a real-world cohort of patients with advanced common solid malignancies","volume":"10","author":"Rolfo","year":"2025","journal-title":"J Liq Biopsy"},{"issue":"18","key":"10.1016\/j.jlb.2026.100504_bib21","doi-asserted-by":"crossref","first-page":"4113","DOI":"10.1158\/1078-0432.CCR-25-3917","article-title":"Role of ctDNA tumor fraction in selecting immunotherapy-based regimens in advanced non-small cell lung cancer","volume":"32","author":"Dall'Olio","year":"2026","journal-title":"Clin Cancer Res"}],"container-title":["The Journal of Liquid Biopsy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950195426000500?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950195426000500?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T03:59:44Z","timestamp":1793073584000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950195426000500"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":21,"alternative-id":["S2950195426000500"],"URL":"https:\/\/doi.org\/10.1016\/j.jlb.2026.100504","relation":{},"ISSN":["2950-1954"],"issn-type":[{"value":"2950-1954","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Circulating tumor DNA tumor fraction as a biomarker in refractory metastatic colorectal cancer: findings from the CAVE-2 GOIM trial","name":"articletitle","label":"Article Title"},{"value":"The Journal of Liquid Biopsy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jlb.2026.100504","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of The International Society of Liquid Biopsy.","name":"copyright","label":"Copyright"}],"article-number":"100504"}}